Across TCGA pan-cancer cohorts, TMEM106A mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of TMEM106A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TMEM106A mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TMEM106A is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

CCRCC and LUAD are the cancer types where TMEM106A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMEM106A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	−0.942	<.001	11	view →
LUAD	Female	III,IV	+0.976	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TMEM106A RNA expression & survival · all TMEM106A data types